Psychotropic medications and substances of abuse interactions in youth

Substance Abuse

Volumn 31, Issue 1, 2010, Pages 53-57

  Kaminer, Yifrah ^a   Goldberg, Pablo ^a   Connor, Daniel F ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

Adolescent substance abuse; Drug interaction; Pharmacotherapy; Psychiatric comorbidity; Treatment

Indexed keywords

PSYCHOTROPIC AGENT; STREET DRUG;

ADOLESCENT; CHILD; DRUG INTERACTION; HUMAN; INFANT; PRESCHOOL CHILD; PSYCHIATRIC DIAGNOSIS; REVIEW;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; DIAGNOSIS, DUAL (PSYCHIATRY); DRUG INTERACTIONS; HUMANS; INFANT; PSYCHOTROPIC DRUGS; STREET DRUGS;

EID: 77951134334     PISSN: 08897077     EISSN: 15470164     Source Type: Journal    
DOI: 10.1080/08897070903442665     Document Type: Article

References (25)

1. NIDA. NIDA's 2008 Monitoring the Future Survey. Downward Trend in Teen Marijuana Use Slows: Prescription Drug Abuse Remains High. Available at: http://drugabuse.gov. Accessed December 11, 2008.
2. McCabe SE, Boyd CJ, Young A. Medical and nonmedical use of prescription drugs among secondary school students. J Adolesc Health. 2007;40:76-83.
3. Substance Abuse and Mental Health Services Administration. Results from the 2005 National Survey on Drug Use and Health: National Findings. Rockville, MD: Office of Applied Studies; 2006. NSDUH Series H-30. DHHS Publication No. SMA 06-4194.
4. Schepis TS, Krishnan-Sarin S. Characterizing adolescent prescription misusers: a population-based study. J Am Acad Child Adolesc Psychiatry. 2008;47:745-754.
5. Shuglin AT. Drugs of abuse in the future. Clin Toxicol. 1975;8:405-457.
6. White W. DXM drug culture. DXM, FAQ, 1997. http://www.erowid.org/chemicals/dxm.php. Accessed December 23, 2008.
7. Kaminer Y, Bukstein OG. Adolescent Substance Abuse: Psychiatric Comorbidity and High Risk Behaviors. New York: Routledge/Taylor & Francis; 2008.
8. Khantzian EJ. The self-medication hypothesis of substance use disorders: a reconsideration and recent applications. Harv Rev Psychiatry. 1997;4:231-244.
9. Degenhardt L, HallW, LynskeyM. Exploring the association between cannabis use and depression. Addiction. 2003;98:1493-1504.
10. Tomlinson KL, Tate SR, Anderson KG, McCarthy D, Brown SA. An examination of self-medication and rebound effects: psychiatric symptomatology before and after alcohol or drug relapse. Addict Behav. 2005;31:461-574.
11. Cornelius JR, Clark DB, Bukstein OG, Birmaher B, Salloum IM, Brown SA. Acute phase and five-year followup study of fluoxetine in adolescents with major depression and a comorbid substance use disorder: a review. Addict Behav. 2005;30:1824-1833.
12. Riggs PD, Mikulich SK, Davies RD, Lohman M, Klein C, Stover SK. A randomized controlled trial of fluoxetine and cognitive behavioral therapy in adolescents with major depression, behavior problems, and substance use disorders. Arch Pediatr Adolesc Med. 2007;161:1026-1034.
13. Brent DA, Perper JA, Goldstien CE, Kolko DJ, Allan MJ, Allman CZ, Zelanak JP. Risk factors for adolescent suicide: a comparison of adolescent suicide victims with suicidal inpatients. Arch Gen Psychiatry. 1988;45:581-588.
14. Fleischmann A, Bertolote JM, Belfer M, Beautries M. Completed suicide and psychiatric diagnosis in young people: a critical examination of the evidence. Am J Orthopsychiatry. 2005;676-683.
15. Goldston D, Daniel S, Erkanli A, Reboussin BA, Mayfield A, Frazier PH, Treadway SL. Psychiatric disorders as contemporaneous risk factors for suicide attempts among adolescents and young adults: developmental stages. J Consult Clin Psychol. In press.
16. Venkatakrishnan K, Shader RI, Greenblatt DJ. Concepts andmechanisms of drug disposition and drug interactions. In: Ciaulo DA, Shader RI, Greenblatt DJ, Creelman W (eds.). Drug Interactions in Psychiatry. Philadelphia: Lippincott Williams & Wilkins; 2006:1-46.
17. Phillips DP, Barker GEC, Eguchi MM. A steep increase in domestic fatal medication errors with use of alcohol and/or street drugs. Arch Intern Med. 2008;168;1561-1566.
18. Volkow ND. The reality of comorbidity: depression and drug abuse. Biol Psychiatry. 2004;56:714-717.
19. Darke S, Ross J. The use of antidepressants among injecting drug users in Sydney, Australia. Addiction. 2000;95:407-417.
20. Kerr JS, Powell J, Hindmarch I. The effects of reboxetine and amitriptyline, with and without alcohol on cognitive function and psychomotor performance. Br J Clin Pharmacol. 1996;42:239-241.
21. Wilens TE, Biederman J, Spencer TJ. Case study: adverse effects of smoking marijuana while receiving tricyclic antidepressants. J Am Acad Child Adolesc Psychiatry. 1997;36:45-48.
22. Wilens TE, Monuteaux MC, Snyder LE, Moore H, Whitley J, Giganc M. The clinical dilemma of using medications in substance-abusing adolescents and adults with ADHD: what does the literature tell us? J Child Adolesc Psychopharmacol. 2005;15:787-798.
23. Goode S. Beer, vodka, morphine: teen final hours. Hartford Courant December 23, 2008, p. 1.
24. Wilens TE, Gignac A, Swezey A, Monuteaux M, Biderman J. Characteristics of adolescents and young adults with ADHD who divert or misuse their prescribed medications. J Am Acad Child Adolesc Psychiatry. 2006;45:408-414.
25. Wilens TE. Attention deficit hyperactivity disorder and adolescent substance use disorder. In: Kaminer Y, Bukstein OG (eds.). Adolescent Substance Abuse: Psychiatric Comorbidity and High Risk Behaviors. New York: Routledge/Taylor & Francis; 2008:195-220.